AC Immune (ACIU) Share-based Compensation (2015 - 2025)
AC Immune (ACIU) posted quarterly Share-based Compensation of $1.1 million for Q4 2025, up 2.46% year-over-year from $1.1 million in Q4 2024, and up 11.29% quarter-over-quarter from $1.0 million in Q3 2025.
AC Immune (ACIU) Share-based Compensation (2015 - 2025) Analysis & Trends
AC Immune (ACIU) has reported Share-based Compensation for 11 consecutive years, with $1.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Share-based Compensation rose 2.46% year-over-year to $1.1 million; the TTM figure through Dec 2025 stood at $5.2 million (down 15.82% YoY), while the FY2025 annual figure was $5.3 million, down 15.09% from the prior year.
- Share-based Compensation rose to $1.1 million in Q4 2025 per ACIU's latest filing, from $1.0 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $2.2 million in Q1 2024 and bottomed at $574678.4 in Q3 2022.
- Historically, Share-based Compensation has averaged $1.2 million across 5 years, with a median of $1.1 million in 2024.
- Annual changes were most pronounced in 2022 — Share-based Compensation sank 61.96% — and 2023, when it surged 70.8%.
- AC Immune's Share-based Compensation stood at $1.1 million in 2021, then retreated by 18.57% to $922801.5 in 2022, then fell by 2.63% to $898501.5 in 2023, then rose by 22.85% to $1.1 million in 2024, then increased by 2.46% to $1.1 million in 2025.
- Business Quant data shows ACIU's Share-based Compensation at $1.1 million in Q4 2025, $1.0 million in Q3 2025, and $1.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | AC Immune | 253.89 Mn | 253.89 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.13 Mn |
| Dec 31, 2025 | 1.13 Mn |
| Sep 30, 2025 | 1.02 Mn |
| Sep 30, 2025 | 1.02 Mn |
| Jun 30, 2025 | 1.35 Mn |
| Jun 30, 2025 | 1.35 Mn |
| Mar 31, 2025 | 1.73 Mn |
| Mar 31, 2025 | 1.73 Mn |
| Dec 31, 2024 | 1.10 Mn |
| Dec 31, 2024 | 1.10 Mn |
| Sep 30, 2024 | 1.42 Mn |
| Sep 30, 2024 | 1.42 Mn |
| Jun 30, 2024 | 1.54 Mn |
| Jun 30, 2024 | 1.54 Mn |
| Mar 31, 2024 | 2.16 Mn |
| Mar 31, 2024 | 2.16 Mn |
| Dec 31, 2023 | 898,501.52 |
| Dec 31, 2023 | 898,501.52 |
| Sep 30, 2023 | 981,576.27 |
| Sep 30, 2023 | 981,576.27 |